The Role of the Triglyceride-Glucose Index in Determining the Risk of Chronic Total Occlusion in Coronary Artery Disease
Trial Snapshot
- Phase
- Not Applicable
- Status
- Not yet recruiting
- Sponsor
- Enrollment
- 200
- Locations
- 1
- Primary Endpoint
- The primary outcome measure will be the difference in the triglyceride-glucose (TyG) index between patients with chronic total occlusion (CTO) and those without CTO, assessed from routinely obtained blood samples.
Study Overview
Brief Summary
We retrospectively analyzed 200 CAD patients undergoing coronary angiography between 2026-2027. Patients were grouped by CTO presence. Clinical and laboratory parameters were compared, and logistic regression was performed to identify independent predictors.
Study Design
- Study Type
- Observational
- Observational Model
- Cohort
- Time Perspective
- Cross Sectional
Eligibility Criteria
- Ages
- 18 Years to — (Adult, Older Adult)
- Sex
- All
- Accepts Healthy Volunteers
- Yes
Inclusion Criteria
- •Adults ≥18 years of age, patients undergoing coronary angiography, non-obese individuals
Exclusion Criteria
- •Patients <18 years of age, history of atrial fibrillation, pacemaker implantation, asthma, pulmonary hypertension, pregnancy, anemia, malignancy, rheumatoid arthritis, or peripheral artery disease, obesity (BMI >30 kg/m²), inaccessible patient records
Arms & Interventions
CTO
CTO (chronic total occlusion)
Intervention: triglyceride-glucose (TyG) index was calculated from routinely obtained blood samples using the formula: Triglyceride (mg/dL) × Glucose (mg/dL) / 2. (Diagnostic Test)
Non CTO
CTO (chronic total occlusion)
Intervention: triglyceride-glucose (TyG) index was calculated from routinely obtained blood samples using the formula: Triglyceride (mg/dL) × Glucose (mg/dL) / 2. (Diagnostic Test)
Outcomes
Primary Outcomes
The primary outcome measure will be the difference in the triglyceride-glucose (TyG) index between patients with chronic total occlusion (CTO) and those without CTO, assessed from routinely obtained blood samples.
Time Frame: 1 Year
Secondary Outcomes
No secondary outcomes reported
Investigators
Rukiye Gonen Ozdemir
M.D
Kırıkkale University